Item(by='jessriedel', descendants=None, kids=[25163826, 25165375, 25164854, 25163855], score=None, time=1605898845, title=None, item_type='comment', url=None, parent=25136697, text='Sorta a tangent but<p>&gt; In a recent policy proposal, we argue that there currently is little credible evidence to support strengthening or weakening patent protection, such as by modifying patent-eligibility standards.<p>What is the best argument that, for example, software patents and pharmaceutical patents should continue to have the same lifetime (20 years)?  On the face it seems <i>insane</i>.<p>In their longer white paper, the authors acknowledge that it might make sense for the specific case of pharmaceuticals to get a special carve out:<p>&gt; Although it is unclear what the optimal length of patent protection is, we suggest a pharmaceutical-specific reform that begins the effective market exclusivity period for new drugs at the time of approval for sale in the United States, rather than at the time of patent filing.<p><a href="https:&#x2F;&#x2F;www.hamiltonproject.org&#x2F;assets&#x2F;files&#x2F;Ouellette_Williams_LO_6.16_FINAL.pdf" rel="nofollow">https:&#x2F;&#x2F;www.hamiltonproject.org&#x2F;assets&#x2F;files&#x2F;Ouellette_Willi...</a><p>But I don&#x27;t understand this claim that, putting certain regulatory barriers aside, we should expect patent lifetime to be independent of field:<p>&gt;  ...the patent systemâ€™s goal of providing uniform protection across inventions.<p>Why would we want uniformity?  The best argument I can think of is just that it reduces individual industries from lobbying for greater protection contrary to the public interest.')